Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
American Cancer Society. Key statistics for esophageal cancer. cancer.org/cancer/esophagus-cancer/about/key-statistics.html. Accessed July 10, 2021.
Andre T, Shiu K-K, Kim TW, et al. Final overall survival for the phase III KEYNOTE-177 study: pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Presented at: 2020 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 3500.
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.
Casak SJ, Marcus L, Fashoyin-Aje L, et al. FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H/dMMR advanced unresectable or metastatic colorectal carcinoma. Clin Cancer Res, 2021;[Epub ahead of print].
Chau I, Doki Y, Ajani JA, et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the CheckMate 648 study. Presented at: 2021 American Society for Clinical Oncology Virtual Meeting. Abstract LBA4001.
Fam-trastuzumab deruxtecan-nxki [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo; 2021.
Janjigian Y, Kawazoe A, Yanez P, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: initial findings of the global phase 3 KEYNOTE-811 study. Presented at: 2021 American Society for Clinical Oncology Virtual Meeting. Abstract 4013.
Janjigian Y, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27-40.
Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): expanded efficacy and safety analyses from CheckMate 577. Presented at: 2020 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 4003.
Le DT, Uram JN, Wan H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-2520.
Moehler MH, Shitara K, Garrido M, et al. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): expanded efficacy and safety data from CheckMate 649. Presented at: 2021 American Society for Clinical Oncology Virtual Meeting. Abstract 4002.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines®) for colorectal cancer v2.2021. www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed July 12, 2021.
Nivolumab [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2021.
Pembrolizumab [prescribing information]. Whitehouse Station, NJ: Merck & Co.; 2021.
Sahin IH, Akce M, Alese O, et al. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 2019;121:809-818.
Yoshino T, Di Bartolomeo M, Raghav KPS, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). Presented at: 2020 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 3505.
Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19:5598-5606.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.